Global Biologics Drug Development Market Analysis and Forecast, 2018-2027: Focus on Facility, Service, Product Type, Country Analysis, and Market Dynamics - ResearchAndMarkets.com
The "Global Biologics Drug Development Market: Focus on Facility, Service, Product Type, Country Analysis, and Market Dynamics - Analysis and Forecast, 2018-2027" report has been added to ResearchAndMarkets.com's offering.
The pharmaceutical industry is a multibillion market consisting of innovator drugs and generics. The pharmaceutical market consists of companies involved in the research, development, manufacturing, and commercialization of drugs for human and animal use. The evolving healthcare needs across the world has led to the rise of novel medication for the treatment of various chronic diseases. Biologics is one such type of medication with proven efficacy and safety.
Biologics are defined as pharmaceutical products obtained from living cells or microorganisms. These are complex and large molecules consisting of proteins, peptides, nucleic acids, sugars, and cellular structures or a combination of these. The pharmaceutical industry is shifting toward biologic drug products due to their advantages over small molecule such as minimal toxicity and safety issues, high target specificity, and better understood mechanism of action. These factors prompt increased interest in the biologics; hence, there is a higher trend toward their discovery and development process.
The biologics drug development involves different types of services for the development of biologics as well as facility for their manufacture. The market can be segmented based on facility into in-house, outsource, and PharmaExcess. Based on services the market can be segmented into clinical manufacturing, formulation development, bioassay development, and analytical services.
Based on the product class, monoclonal antibody is anticipated to be the major contributor to the market. However, the fastest growing segment is expected to be growth factors market. Geographically, the market is segmented into four regions namely, North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World.
The purpose of the study is to gain a holistic view of the biologics drug development market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of the report is centered upon conducting a detailed study of the solutions allied with the biologics drug development market. The market has been segmented into product class', facility', services', and geographical regions'.
The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
This research report aims at answering various aspects of the global biologics drug discovery market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that is going to shape the future trajectory of the market expansion.
Key Topics Covered:
1 Market Overview
2 Market Dynamics
3 Competitive Landscape
4 Biologics Drug Development Market, (by Class)
5 Biologics Drug Development Market, (by Facility)
6 Biologics Drug Development Market, (by Services)
7 Biologics Drug Development Market, (by Region)
8 Company Profiles
9 Consumer Perception (Pharmaceutical Companies) on Clinical Manufacturing of Biologics Drugs
10 Report Scope and Methodology
- AbbVie Inc.
- Amgen, Inc.
- Boehringer Ingelheim International GmbH
- Catalent Inc.
- Charles River Laboratories
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc
- KBI Biopharma
- MabPlex Inc.
- Samsung BioLogics
- Singota Solutions
- WuXi Biologics
For more information about this report visit https://www.researchandmarkets.com/research/xrnr6z/global_biologics?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181126005366/en/